DE69518415D1 - Arznei für rheumatoide arthritis - Google Patents

Arznei für rheumatoide arthritis

Info

Publication number
DE69518415D1
DE69518415D1 DE69518415T DE69518415T DE69518415D1 DE 69518415 D1 DE69518415 D1 DE 69518415D1 DE 69518415 T DE69518415 T DE 69518415T DE 69518415 T DE69518415 T DE 69518415T DE 69518415 D1 DE69518415 D1 DE 69518415D1
Authority
DE
Germany
Prior art keywords
rheumatoid arthritis
medicine
remedy
monoclonal antibody
antibody recognizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69518415T
Other languages
English (en)
Other versions
DE69518415T2 (de
Inventor
Tadashi Nishida
Sachiko Miyake
Hideo Yagita
Ko Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Application granted granted Critical
Publication of DE69518415D1 publication Critical patent/DE69518415D1/de
Publication of DE69518415T2 publication Critical patent/DE69518415T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69518415T 1994-04-26 1995-03-22 Arznei für rheumatoide arthritis Expired - Fee Related DE69518415T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8825194 1994-04-26
PCT/JP1995/000527 WO1995028961A1 (fr) 1994-04-26 1995-03-22 Medicament pour polyarthrite rhumatoide

Publications (2)

Publication Number Publication Date
DE69518415D1 true DE69518415D1 (de) 2000-09-21
DE69518415T2 DE69518415T2 (de) 2001-01-25

Family

ID=13937651

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69518415T Expired - Fee Related DE69518415T2 (de) 1994-04-26 1995-03-22 Arznei für rheumatoide arthritis

Country Status (9)

Country Link
US (1) US5855888A (de)
EP (1) EP0759302B1 (de)
AT (1) ATE195428T1 (de)
DE (1) DE69518415T2 (de)
DK (1) DK0759302T3 (de)
ES (1) ES2151054T3 (de)
GR (1) GR3034200T3 (de)
PT (1) PT759302E (de)
WO (1) WO1995028961A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020030A1 (en) * 1998-10-07 2000-04-13 Karolinska Innovations Ab Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies
CN100360183C (zh) * 1999-04-22 2008-01-09 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物中的用途
NZ515686A (en) 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
US6146639A (en) * 1999-07-26 2000-11-14 Merich Nick Arthritis, muscle pain, and dry skin remedy
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
US20030013107A1 (en) * 2001-06-07 2003-01-16 Rigel Pharmaceuticals, Incorporated Alpha 2 integrin: modulators of lymphocyte activation
EP3023497A1 (de) * 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2-integrin-antikörper und deren verwendungen
JP5496658B2 (ja) * 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
EP3623381A1 (de) * 2011-05-19 2020-03-18 The Regents Of The University Of Michigan Alpha-2-integrin-bindemittel und verwendung zur hemmung der krebszellenproliferation
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (de) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute VLA-Proteine
DK162890D0 (da) * 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
AU673499B2 (en) * 1991-07-25 1996-11-14 Biogen Idec Inc. Recombinant antibodies for human therapy

Also Published As

Publication number Publication date
EP0759302A1 (de) 1997-02-26
ATE195428T1 (de) 2000-09-15
GR3034200T3 (en) 2000-11-30
ES2151054T3 (es) 2000-12-16
WO1995028961A1 (fr) 1995-11-02
PT759302E (pt) 2001-01-31
DK0759302T3 (da) 2000-11-13
EP0759302A4 (de) 1997-11-19
DE69518415T2 (de) 2001-01-25
EP0759302B1 (de) 2000-08-16
US5855888A (en) 1999-01-05

Similar Documents

Publication Publication Date Title
ATE195428T1 (de) Arznei für rheumatoide arthritis
ITMI921522A0 (it) Apparato di lavaggio e sterilizzazione di tappi di gomma, o simili impiegabili in confezioni farmaceutiche
ATE138569T1 (de) Topisch anzuwendendes arzneimittel enthaltend ketoprofenlysinat
DE69530316D1 (de) Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
FI932958A (fi) Elastisk paose foer att packa in sammantryckbara produkter, speciellt sanitetsartiklar saosom bloejor, samt en foerpackning i vilken sammantryckta sanitetsprodukter foerpackats
BR9607414A (pt) Utilizaçao de aerogéis inorgânicos em farmacologia
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
FI893159A (fi) Laite ja menetelmä terveydenhuollossa syntyvien ongelmajätteiden käsittelemiseksi
FI961525A0 (fi) Uusi emulsioformulaatio
BR9406292A (pt) Complexo de inclusão de taxol ou taxotere ou extrato de taxus formados com ciclodextrinas sua preparação e uso
ATE314068T1 (de) Behandlung von seborrhoischer dermatitis
FR2656214B1 (fr) Cadre dynamique d'osteosynthese du rachis.
ATE433339T1 (de) Parasympathikomimetikum und parasympathikolytikum enthaltendes tts
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
SE9404331L (sv) Förfarande för sträckning av en materialbana vid framställning av vätskeabsorberande alster och anordning för materialbanans sträckning
ITRM910545A0 (it) Dispositivo trasportatore di bobine, rocche di filo e simili
ES2187618T3 (es) Utilizacion de compuestos de urea y de tiourea para la eliminacion o desintoxicacion de superantigenos de fluidos corporales.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
KR910700263A (ko) 시클로리노펩티드를 포함하는 의약
IT8819650A0 (it) Apparecchio per la ginnastica attiva del viso e del collo.
KR950701812A (ko) 렌티바이러스-유도된 질환의 치료에 유용한 생물학적으로 활성인 우레이도 유도체(Biologically active ureido dervatives useful in the treatment of lentivirus-induced sisease)
FR2690330B1 (fr) Dispositif destine a traiter certaines fractures siegeant entre massif trochanterien et 1/3 moyen de la diaphyse femorale.
EA199600048A3 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
Matsumura et al. Detection of specific IgM antibodies to toxocaral ES antigen: effect of absorption of sera with protein A sepharose

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AKZO NOBEL N.V., ARNHEIM/ARNHEM, NL

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee